The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure
- First Online:
- 268 Downloads
To compare EQ-5D and SF-6D utilities across groups of chronic heart failure (CHF) patients with varying levels of disease severity.
A consecutive sample (N = 251) of CHF patients undergoing elective cardiac surgery were surveyed. Disease severity was proxied via a self-assessment scale, the EQ-VAS and the Duke Activity Status Index (DASI); however, validity was demonstrated only by the latter. Association and level of agreement between instruments in DASI-based severity groups were estimated with Pearson’s r and the intraclass correlation coefficient (ICC), respectively. Paired-samples t test was used to identify significant differences. In a linear regression model, the DASI was used as an anchor of disease severity to identify a potential “crossover” point between EQ-5D and SF-6D utilities.
EQ-5D and SF-6D strongly correlated over the entire sample (r = 0.647, P < 0.001); however, their agreement was moderate (ICC = 0.484, P < 0.001). In the less severe DASI groups (i.e. higher functional capacity) EQ-5D was significantly higher than SF-6D (P < 0.001) and differences constituted minimally important differences (MIDs). Contrarily, in the more severe groups SF-6D was predominantly higher than EQ-5D. The regression model indicated a utility crossover point at 0.722 and predicted that individuals with a utility score less than this would score higher on the SF-6D than on the EQ-5D, and vice versa. The DASI score at crossover was calculated at 31.94.
In subgroups of patients differing in CHF severity according to the DASI, mean EQ-5D and SF-6D indices differed significantly. Contrarily, in socio-demographic and clinical groups, these utility differences were not directly evident. According to the evidence, comparisons based on severity classification via a valid disease-specific external instrument may provide insight on instrument choice in cost-utility analyses.
KeywordsChronic heart failure Cost-utility analysis Duke activity status index EQ-5D Health-related quality of life SF-6D
- 6.Hobbs, F.D., Kenkre, J.E., Roalfe, A.K., Davis, R.C., Hare, R., Davies, M.K.: Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur. Heart J. 23, 1867–1876 (2002)PubMedCrossRefGoogle Scholar
- 27.Glick, H., Cook, J., Kinosian, B., Pitt, B., Bourassa, M.G., Pouleur, H., et al.: Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. J. Card. Fail. 1, 371–380 (1995)PubMedCrossRefGoogle Scholar
- 28.National Institute for Clinical Excellence: Guide to the methods of technology appraisal. NICE, London (2004)Google Scholar
- 33.Yfantopoulos, J.: The Greek version of the EuroQol (EQ-5D) instrument. Arch. Hell. Med. 18, 180–191 (2001)Google Scholar
- 49.Parissis, J.T., Nikolaou, M., Birmpa, D., Farmakis, D., Paraskevaidis, I., Bistola, V., et al.: Clinical and prognostic value of Duke’s activity status index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 103, 73–75 (2009)PubMedCrossRefGoogle Scholar